Every woman in her late 40s knows the general rule. HDL is the good cholesterol. LDL is the bad one. Keep the first number high and the second one low and your heart is probably fine.

She had been told this for twenty years. Her HDL was consistently high. Her GP checked it annually and commented approvingly. Nobody mentioned that after menopause, the relationship between HDL and cardiovascular protection changes fundamentally.

She found out at a cardiology appointment she booked herself after reading something online at midnight.

She is not unusual. She is the norm.

The cholesterol story most women have been told is incomplete. Not wrong — incomplete. And the part that is missing is specifically relevant to women in the menopause transition, when the standard cardiovascular markers that predict risk in younger women begin to tell a different story.

I want to be precise about this, because “your heart health changes at menopause” is a sentence that produces fear without producing clarity. The mechanism is the thing. And the mechanism here is specific enough that once you understand it, you know exactly which questions to add to your next cardiovascular appointment.

Cardiovascular disease is the leading cause of death in women. The risk does not rise evenly or gradually. It rises at menopause — driven by a specific set of changes in lipid quality, vascular function, and fat distribution that are independent of aging, independent of diet, and independent of lifestyle choices that were adequate before the hormonal transition.

Understanding this is not frightening. It is clarifying. And clarity, at this life stage, is the most actionable thing I can offer.

The SWAN study finding that changed how I think about cholesterol

The Study of Women’s Health Across the Nation, known as the SWAN study, has followed thousands of women through the full menopause transition and produced some of the most important longitudinal data on women’s cardiovascular health that exists. One of its findings is almost never communicated to the women who need it most.

LDL cholesterol — the form of cholesterol associated with arterial plaque build-up — increases dramatically within the year surrounding the final menstrual period. This increase is independent of aging. The same woman, eating the same food, exercising the same way, will show a measurable and often sharp rise in LDL cholesterol in the months around her last period. This is estrogen withdrawal, expressed in her lipid panel.

The SWAN data also confirmed changes in apolipoprotein B — a protein that coats LDL particles and enables them to embed in arterial walls. Rising apolipoprotein B is one of the strongest predictors of cardiovascular event risk, and it is not part of the standard cholesterol panel most women receive annually.

But the HDL finding is perhaps the most important — and the least known.

Why your HDL may not be doing what you think it is

HDL cholesterol has been understood as protective for decades. It carries cholesterol away from the arterial wall and back to the liver for processing. Before menopause, high HDL levels are reliably associated with lower cardiovascular risk.

After menopause, this relationship shifts. The SWAN study found that HDL quality — not just quantity — undergoes a significant change during the menopause transition. The HDL particles themselves become less functional. And the Dallas Heart Study (published by the European Society of Cardiology in 2024), which measured advanced lipoprotein subfractions using nuclear magnetic resonance technology in 1,246 women with known menopause status, found something that cardiologists are still working to fully incorporate into clinical guidance: higher HDL levels, which are protective before menopause, are associated with greater carotid atherosclerosis — the measurable narrowing and hardening of the carotid arteries — after menopause.

Carotid intima-media thickness, which is the clinical measurement of the inner layers of the carotid artery wall, is one of the most reliable subclinical markers of cardiovascular risk. When HDL stops protecting it, the standard panel your GP interprets every year may give you a reassuring number that no longer tells the full story.

This is not a reason for panic. It is a reason to ask for a more comprehensive assessment.

The vascular change happening beneath the surface

At the same time as the lipid profile is shifting, the blood vessels themselves are changing. Estradiol directly activates eNOS — the enzyme that produces nitric oxide inside the endothelium, the thin cellular lining of every blood vessel in the body. Nitric oxide keeps vessels dilated and supple. It prevents the adherence of inflammatory cells to vessel walls. It slows the progression of atherosclerosis.

A 2025 narrative review published in MDPI on cardiovascular disease risk in women in menopause describes the consequence of estrogen withdrawal on this system precisely: endothelial dysfunction, increased arterial stiffness, and impaired nitric oxide-dependent vasodilation develop in a measurable sequence following estrogen decline. Women in perimenopause already show early markers of this process — which is why a 2025 paper in Cardiovascular Health During Menopause Transition describes the perimenopausal period, not the post-menopausal period, as the critical window for cardiovascular risk identification and prevention.

The visceral fat and inflammation cascade

Alongside the lipid and vascular changes, the redistribution of body fat from the hips and thighs to the abdomen — the shift from a gynoid to an android fat distribution pattern — produces its own cardiovascular risk cascade. Visceral fat, the fat stored around the internal organs rather than beneath the skin, is metabolically active in a way that subcutaneous fat is not. It generates pro-inflammatory cytokines — signalling molecules including TNF-alpha, interleukin-6, and C-reactive protein — that drive systemic vascular inflammation and worsen insulin resistance.

Higher insulin resistance means higher chronic insulin levels, which means more LDL particle production and more arterial inflammation. The lipid changes and the fat distribution changes compound each other through the inflammation pathway. And both are driven, at root, by the same upstream cause: estradiol withdrawal.

The conversation to have with your clinician — and what to ask for

A standard annual cholesterol panel typically measures total cholesterol, LDL, HDL, and triglycerides. In the context of the menopause transition, this is not enough. The tests worth asking about by name are: apolipoprotein B (a more reliable marker of atherogenic risk than LDL cholesterol alone), LDL particle number and size (small dense LDL particles are significantly more atherogenic than large buoyant ones, and standard panels do not distinguish between them), hsCRP — high-sensitivity C-reactive protein, a marker of vascular inflammation — and a blood pressure trend over time rather than a single reading.

If your clinician is not already assessing carotid intima-media thickness as a subclinical cardiovascular risk marker, this is worth raising — particularly if you have a family history of cardiac events or have entered menopause before 45.

On the question of hormone therapy and cardiovascular health: the timing window is real, and it is clinically important. A 2025 review in MDPI confirms that hormone therapy initiated before age 60 or within 10 years of the final menstrual period is associated with reduced death from heart disease and from all causes. This is not a blanket recommendation for every woman. It is a clinically significant piece of data that should be part of your individual cardiovascular risk conversation — not a topic deferred until you are 65.

She asked her cardiologist for an apolipoprotein B test, an LDL particle count, and an hsCRP reading, at her follow-up appointment. He ran all three. Her particle count told a more detailed story than her standard panel had. She had information she could act on.

“I wish someone had told me these tests existed three years ago,” she said.

They did exist. Nobody had directed her toward them. Nobody had framed her cardiovascular risk as a menopause transition question.

That framing is what changes the conversation.

Your cholesterol panel is a starting point, not a conclusion. At this life stage, the tests that matter most are the ones designed to detect the specific changes the menopause transition drives — and most of them are not on the standard form.

This week: ask your clinician to add apolipoprotein B to your next lipid panel. One test. One number. One significantly more accurate predictor of cardiovascular risk than the standard panel provides.

That is a small ask with a potentially significant return.